Universal testing grants survival improvements with acceptable costs
HER2-negative, HR-positive HER2-negative
Although significant improvements in the invasive disease-free survival (iDFS) of HER2-negative BC patients receiving adjuvant olaparib have been reported, it could not improve the iDFS of HR-positive HER2-negative BC patients in the subgroup analysis, as reported by the OlympiA study [Current guidelines recommend MBC patients receive gBRCA screening for the potential benefits of survival and QoL improvements from PARPi [